Related Experiment Video
Updated: Aug 6, 2026
07:47
Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker
Published on: September 15, 2023
TMPRSS4 Expression Predicts Survival and Benefit from Neoadjuvant Chemotherapy in Pancreatic Cancer
Kenta Baba1, Takeshi Sudo2, Atsushi Yamaguchi3
1Department of Surgery, NHO Kure Medical Center and Chugoku Cancer Center, Kure, Hiroshima, Japan. baba.kenta.lr@mail.hosp.go.jp.
Annals of Surgical Oncology
|July 17, 2026
Summary
Transmembrane serine protease 4 (TMPRSS4) expression indicates a poor prognosis in pancreatic ductal adenocarcinoma (PDAC). However, TMPRSS4-positive patients may benefit more from neoadjuvant chemotherapy (NAC), suggesting its potential as a predictive marker.
Area of Science:
- Oncology
- Molecular Biology
- Surgical Oncology
Background:
- Transmembrane serine protease 4 (TMPRSS4) promotes pancreatic cancer progression and chemoresistance.
- The role of TMPRSS4 in neoadjuvant chemotherapy (NAC) efficacy for pancreatic ductal adenocarcinoma (PDAC) is not well understood.
Purpose of the Study:
- To investigate the clinical significance of TMPRSS4 expression in resected PDAC.
- To evaluate the prognostic impact of TMPRSS4 and its interaction with NAC.
Main Methods:
- Retrospective analysis of 152 patients with resectable PDAC.
- Immunohistochemical assessment of TMPRSS4 expression.
- Correlation with clinicopathologic factors, survival, and NAC response.
Main Results:
- TMPRSS4 positivity (63%) was associated with larger tumors and poorer overall survival.
- TMPRSS4 expression, larger tumor size, lymph node metastasis, and lack of NAC independently predicted poor survival.
- NAC significantly improved survival in TMPRSS4-positive patients but not in TMPRSS4-negative patients (interaction p=0.032).
Conclusions:
- TMPRSS4 expression is a negative prognostic factor in PDAC.
- TMPRSS4 may serve as a predictive biomarker for NAC treatment stratification in PDAC.